Postdoctor at Guangxi Medical University Cancer Hospital, China
Dr. Ren Jing is a highly accomplished researcher and clinician whose interdisciplinary expertise spans anesthesiology, immunology, and biomedical engineering. As an Associate Researcher and Postdoctoral Fellow, Dr. Jing has demonstrated a significant commitment to understanding the immunological mechanisms behind perioperative organ injury and tumor immune microenvironments. With over a decade of medical education and professional clinical experience, Dr. Jing seamlessly integrates translational research with clinical applications. His work stands out in the realms of perioperative immune regulation, lung injury, and cancer-related immune modulation. His involvement in national and provincial projects, along with his service in international academic alliances and peer review roles, reflects a robust academic presence and leadership in the scientific community.
Profile
Scopus
Education
Dr. Jing holds a Ph.D. in Anesthesiology from Guangxi Medical University, where his doctoral research focused on perioperative immune function and the use of cutting-edge techniques such as CRISPR/Cas9 and high-throughput sequencing. Prior to this, he earned a Master’s degree from the same university, where he investigated immune optimization in patients with lung injuries, utilizing FACS and single-cell RNA sequencing. His educational foundation was laid with a Bachelor’s degree in Anesthesiology from Shenyang Medical College, during which he acquired a deep understanding of pharmacology, immunology, and physiology.
Experience
Dr. Jing’s professional career has been a blend of clinical and research excellence. From 2017 to 2022, he served as a Resident Physician at the Guangxi Medical University Affiliated Cancer Hospital and was later promoted to Attending Physician in 2023. Currently, he is a Postdoctoral Fellow in Biomedical Engineering at South China Hospital of Shenzhen University, where he focuses on the tumor immune microenvironment in thyroid cancer. His clinical background enhances the translational value of his biomedical research, allowing him to explore innovative interventions for perioperative care and oncology.
Research Interest
Dr. Jing’s primary research interest lies in the interplay between immune function and organ injury, especially in perioperative and cancer contexts. He explores how immune cells like macrophages and T cells behave under stress or therapeutic conditions, aiming to regulate inflammation and enhance recovery. In recent years, his focus has expanded to understanding how the tumor microenvironment, particularly in thyroid cancer, can be modulated to improve prognosis. His research is supported by various prestigious grants and has contributed significantly to knowledge in immunopharmacology, ventilator-induced lung injury, and mitochondrial signaling pathways.
Award
Dr. Jing was honored as a “2024 Shenzhen Outstanding Postdoctoral Fellow,” a recognition that highlights his scientific rigor and impact. Additionally, he has served as an expert evaluator for the Shenzhen Municipal Development and Reform Commission for Special Funds. In 2023, he received the First Class Award for Scientific and Technological Progress from Guangxi, reflecting the high quality and relevance of his contributions to scientific advancement. These accolades underscore his role as a rising leader in biomedical research.
Publication
Dr. Jing has published over 33 papers, with 21 indexed in SCI journals. Notable recent publications include:
-
Jing R, et al. (2024). “DPP4 promotes an immunoenhancing tumor microenvironment through exhausted CD8+ T cells with activating IL13-IL13RA2 axis in papillary thyroid cancer.” International Immunopharmacology, 145:113760.
— This work has been cited for advancing tumor immunotherapy targeting IL13 pathways.
-
Jing R, et al. (2024). “Transforming growth factor-β1 is associated with inflammatory resolution via regulating macrophage polarization in lung injury model mice.” International Immunopharmacology, 142:112997.
— Cited in articles addressing immune modulation in acute lung injury.
-
Jing R, et al. (2023). “Transforming growth factor-β1 attenuates inflammation and lung injury with regulating immune function in ventilator-induced lung injury mice.” International Immunopharmacology, 114:109462.
— Widely referenced for its insight into ventilator-induced lung injury.
-
Jing R, et al. (2020). “Mitophagy-Mediated mtDNA Release Aggravates Stretching-Induced Inflammation and Lung Epithelial Cell Injury via the TLR9/MyD88/NF-κB Pathway.” Frontiers in Cell and Developmental Biology, 8:819.
— Frequently cited in mitochondrial signaling and immune studies.
-
Lin JY#, Jing R#, et al. (2018). “High Tidal Volume Induces Mitochondria Damage and Releases Mitochondrial DNA to Aggravate the Ventilator-Induced Lung Injury.” Frontiers in Immunology, 9:1477.
— Key reference in the field of ventilator-associated complications.
Conclusion
In summary, Dr. Ren Jing’s career exemplifies the convergence of clinical practice and innovative research. His dedication to uncovering the mechanisms of immune regulation during surgical stress and cancer progression has led to valuable insights and therapeutic implications. Through a strong publication record, prestigious awards, and leadership in scientific organizations, Dr. Jing has established himself as a credible and impactful figure in anesthesiology and immunology. His work continues to shape perioperative and oncological treatment strategies, making him a deserving nominee for any distinguished research award.